Search Results

M2S and NAMSA Collaboration Will Nest Premarket Vascular Device Trials in Registries

June 22, 2021—M2S, a division of Medstreaming, and NAMSA announced a strategic collaboration combining M2S’s medical registry services and NAMSA’s expertise as a Contract Research Organization (CRO) to provide clinical trial services for vascular device manufacturers.

Study Shows Use of VQI Registry Data to Support FDA Decisions Yields a High Return on Investment

November 3, 2020—Findings from a study conducted to determine the potential value (cost-saving, time-saving, and return on investment) created by device evaluation studies using the Society for Vascular Surgery Vascular Quality Initiative (VQI) registry infrastructure were published by Jack L. Cronenwett, MD, et al online in the open-access BMJ Surgery, Interventions, & Health Technologies.

Lombard Medical Engages SVS and M2S for Postmarket Surveillance of Aorfix

September 24, 2014—Lombard Medical announced that it has partnered with the Society for Vascular Surgery Patient Safety Organization (SVS PSO) and M2S Inc. to develop a US Food and Drug Administration- (FDA-) required postmarketing surveillance program for the company’s Aorfix endovascular stent graft, which is used to treat abdominal aortic aneurysm (AAA).

Vascular Disease Foundation Seeks Nominations for Jacobson Award

January 25, 2011—The Vascular Disease Foundation announced that February 11 is the deadline to submit nominations for the 2011 Julius H. Jacobson II Award for Physician Excellence. Information about the Jacobson Award and nomination applications are available on the Vascular Disease Foundation's Web site at www.vdf.org.

SVS Launches Vascular Quality Initiative

November 11, 2010—The Society for Vascular Surgery (SVS) announced a new quality initiative to improve the care of patients with vascular disease.

SVS Issues Commentary on CREST-2

On behalf of the Society for Vascular Surgery (SVS), Ali AbuRahma, MD, Past President of SVS; Marc Schermerhorn, MD, Past Chair, SVS Document Oversight Committee; and Keith Calligaro, MD, President, SVS and SVS Executive Board, provided the following commentary on the CREST-2 results to Endovascular Today: The purpose of this commentary is to critically examine the CREST-2 results, discuss their implications for clinical decision-making for asymptomatic carotid artery disease, and guide clinicians toward optimizing patient outcomes.